AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients

被引：0

作者：

Gartland, M ^{[1
]}

Gerstoft, J ^{[1
]}

Goebel, F ^{[1
]}

Clumeck, N ^{[1
]}

Cooper, DA ^{[1
]}

Gatell, J ^{[1
]}

Gazzard, B ^{[1
]}

Gerstoft, J ^{[1
]}

Goebel, F ^{[1
]}

Lange, J ^{[1
]}

Montaner, J ^{[1
]}

Reiss, P ^{[1
]}

Rozenbaum, W ^{[1
]}

Vella, S ^{[1
]}

Beveridge, A ^{[1
]}

Cooper, DA ^{[1
]}

Duncombe, C ^{[1
]}

Gold, J ^{[1
]}

Haberl, M ^{[1
]}

Clumeck, N ^{[1
]}

Luyts, D ^{[1
]}

Montaner, J ^{[1
]}

Rachlis, A ^{[1
]}

Marina, R ^{[1
]}

Gerstoft, J ^{[1
]}

Wandall, JH ^{[1
]}

Elbrond, B ^{[1
]}

Molina, JM ^{[1
]}

Pialloux, G ^{[1
]}

Rozenbaum, W ^{[1
]}

Beauvais, L ^{[1
]}

Goebel, FD ^{[1
]}

Staszewski, S ^{[1
]}

Bruns, I ^{[1
]}

Hug, M ^{[1
]}

Reiss, P ^{[1
]}

Lange, J ^{[1
]}

Frissen, PHJ ^{[1
]}

van der Ende, ME ^{[1
]}

Bosboom, M ^{[1
]}

Baas, C ^{[1
]}

Milazzo, F ^{[1
]}

Moroni, M ^{[1
]}

Panebianco, R ^{[1
]}

Clotet, B ^{[1
]}

Artigas, JMG ^{[1
]}

Gonzalez-Lahoz, J ^{[1
]}

Leal, M ^{[1
]}

Rodriguez-Lopo, C ^{[1
]}

Gandarias, B ^{[1
]}

机构：

[1] Glaxo Wellcome Res & Dev Ltd, Greenford UB6 0HE, Middx, England

来源：

AIDS | 2000年 / 14卷 / 04期

关键词：

antiretroviral therapy; clinical trials; combination therapy; protease inhibitors; reverse transcriptase inhibitors;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objectives: To investigate the effect of combination antiretroviral therapy on plasma HIV-1 RNA as measured by HIV RNA PCR and to assess their safety and tolerability. Design: A randomized, multicentre, double-blind, placebo-controlled trial. Setting: Multicentre study in eight European countries, Australia and Canada. Patients: Antiretroviral naive patients (n = 103) with CD4 cell counts between 150 and 500 x 10(6)/I. Intervention: Patients were randomly assigned to zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150mg twice per day) or to ZDV + 3TC + indinavir (IND; 800 mg q8h) for 52 weeks. Main outcome measures: Degree and duration of reduction of plasma HIV-1 RNA as measured by RNA PCR; Development of drug-related toxicities sufficiently severe to warrant dose modification, interruption or permanent discontinuation. Results: ZDV + 3TC + IND reduced plasma HIV-1 RNA (P < 0.001) and increased CD4 cell count significantly (P = 0101) more than ZDV + 3TC. The addition of IND to ZDV + 3TC as initial therapy markedly increased the proportion of patients with plasma HIV-1 RNA values 500 copies/ml (31/52, 60%) or 20 copies/ml (24/52, 46%) as compared with ZDV + 3TC (9/50, 18% or 2/50, 4% respectively) at week 52 in an intention-to-treat, missing = failure analysis. Assessment of time to virological rebound (> 0.5 log(10) copies/ml above nadir) showed that patients who attained a minimum plasma HIV-1 RNA of less than or equal to 20 copies/ml were less likely to rebound than those who did not reach this threshold. The addition of IND to ZDV + 3TC did not result in any significant increase in adverse experiences. Conclusion: ZDV + 3TC + IND resulted in a considerable improvement compared with the double combination, in reduction in plasma HIV-1 RNA, increase in CD4 cell count and proportion of patients with HIV RNA below the limit of detection. Despite an average 3 log(10) decrease in plasma HIV-1 RNA on triple therapy, however, maximal suppression (less than or equal to 20 copies/ml) was only attained in about one-half of the patients in an intent-to-treat analysis. (C) 2000 Lippincott Williams & Wilkins

引用

页码：367 / 374

页数：8

共 16 条

[1]

Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1

[2] Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection [J].

Bartlett, JA ;

Benoit, SL ;

Johnson, VA ;

Quinn, JB ;

Sepulveda, GE ;

Ehmann, WC ;

Tsoukas, C ;

Fallon, MA ;

Self, PL ;

Rubin, M .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (03) :161-+

[3] Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].

Carpenter, CCJ ;

Fischl, MA ;

Hammer, SM ;

Hirsch, MS ;

Jacobsen, DM ;

Katzenstein, DA ;

Montaner, JSG ;

Richman, DD ;

Saag, MS ;

Schooley, RT ;

Thompson, MA ;

Vella, S ;

Yeni, PG ;

Volberding, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969

[4] COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE COMPARED WITH ZIDOVUDINE ALONE IN HIV-1 INFECTION [J].

COLLIER, AC ;

COOMBS, RW ;

FISCHL, MA ;

SKOLNIK, PR ;

NORTHFELT, D ;

BOUTIN, P ;

HOOPER, CJ ;

KAPLAN, LD ;

VOLBERDING, PA ;

DAVIS, LG ;

HENRARD, DR ;

WELLER, S ;

COREY, L .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :786-793

[5]

Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3

[6]

Deeks S., 1997, 37 INT C ANT AG CHEM

[7] TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].

ERON, JJ ;

BENOIT, SL ;

JEMSEK, J ;

MACARTHUR, RD ;

SANTANA, J ;

QUINN, JB ;

KURITZKES, DR ;

FALLON, MA ;

RUBIN, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669

[8] COMBINATION AND MONOTHERAPY WITH ZIDOVUDINE AND ZALCITABINE IN PATIENTS WITH ADVANCED HIV DISEASE [J].

FISCHL, MA ;

STANLEY, K ;

COLLIER, AC ;

ARDUINO, JM ;

STEIN, DS ;

FEINBERG, JE ;

ALLAN, JD ;

GOLDSMITH, JC ;

POWDERLY, WG ;

RAINES, CP ;

MAYJO, KJ ;

KERULY, JC ;

CRAVEN, D ;

HIRSHORN, L ;

HIRSCH, MS ;

JAYAWEERA, DT ;

YOUNG, SW ;

PATRONEREESE, J ;

BRETTLER, D ;

SPERBER, K ;

GERITS, P ;

SEREMETIS, S ;

GILL, JC ;

GELB, LD ;

MCGUIRE, ML ;

STIFFLER, T ;

LEDERMAN, MM ;

CAREY, JT ;

WALLACE, M ;

MACARTHUR, RD ;

BERGE, P ;

MILDVAN, D ;

COREY, L ;

COOMBS, RW ;

CUMMINGS, DK ;

SCHOOLEY, RT ;

RAY, MG ;

WAITE, V ;

KURITZKES, DR ;

FUHRER, J ;

TENZLER, RJ ;

DONLON, W ;

VANDERHORST, CM ;

TROIANI, L ;

HORTON, J ;

LANE, TW ;

MURPHY, RR ;

PHAIR, JP ;

KESSLER, HA ;

BENSON, CA .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) :24-32

[9] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Gonzalez, C ;

McMahon, D ;

Richman, DD ;

Valentine, FT ;

Jonas, L ;

Meibohm, A ;

Emini, EA ;

Chodakewitz, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739

[10] Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection - 100-week follow-up [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Gonzalez, C ;

McMahon, D ;

Jonas, L ;

Meibohm, A ;

Holder, D ;

Schleif, WA ;

Condra, JH ;

Emini, EA ;

Isaacs, R ;

Chodakewitz, JA ;

Richman, DD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :35-41

← 1 2 →